Beta DrugsNSE:BETA +1.00%86 Pretax Margin % is 12.59% as of Mar. 2026, which is 10% below its 10-year median of 13.94. GuruFocus rates NSE:BETA with a GF Score™ of 86/100 and a GF Value™ of ₹1,965.84 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Beta Drugs ranks better than 62.96% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Beta Drugs's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹118 Mil. Beta Drugs's Revenue for the
three
months ended in Mar. 2026 was ₹940 Mil. Therefore, Beta Drugs's pretax margin for the quarter that ended in Mar. 2026 was 12.59%.
The historical rank and industry rank for Beta Drugs's Pretax Margin % or its related term are showing as below:
NSE:BETA'
s Pretax Margin % Range Over the Past 10 Years
Min: 11.99 Med: 13.94 Max: 18.66
Current: 12.31
NSE:BETA's Pretax Margin % is ranked better than 62.96% of 953
companies
in the Drug Manufacturers industry
Industry Median: 7.3
vs NSE:BETA: 12.31
Beta Drugs (NSE:BETA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Beta Drugs Pretax Margin % Related Terms
Beta Drugs Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Pretax Margin % of 12.59% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beta Drugs and its competitors. This is 10% below median its historical median of 13.94. Over the past decade, Beta Drugs' Pretax Margin % has ranged from 11.99 to 18.66. According to the industry distribution chart, Beta Drugs ranks #353 out of 953 companies in the Drug Manufacturers industry, placing it in the top 37%.
Is Beta Drugs' Pretax Margin % too high?
Beta Drugs' current Pretax Margin % of 12.59% is 10% below median its 10-year median of 13.94. Over the past 10 years, this metric has ranged from a low of 11.99 to a high of 18.66. The Drug Manufacturers industry median Pretax Margin % is 7.30. Beta Drugs' value of 12.59% is 72.5% above this industry median. Based on the distribution chart, Beta Drugs ranks #353 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #353 out of 953 companies for Pretax Margin %. This puts Beta Drugs in the upper half of its industry. The industry median Pretax Margin % is 7.30. Beta Drugs' value of 12.59% is 72.5% above this benchmark. Historically, Beta Drugs' own Pretax Margin % has ranged from 11.99 to 18.66 over the past decade. While the company's 10-year median is 13.94 vs. the industry median of 7.30, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Pretax Margin % of 12.59% is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Pretax Margin % is 12.59%, which is 10% below median its own 10-year median of 13.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,965.84, compared to a current price of ₹2,184.70 — trading 11.1% above its estimated fair value. The current Pretax Margin % is 12.59%, which is 10% below median its 10-year median of 13.94 and 72.5% above the Drug Manufacturers industry median of 7.30. Beta Drugs' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Pretax Margin % is 12.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,184.70 is trading 11.1% above its estimated GF Value™ of ₹1,965.84.
GuruFocus considers Beta Drugs to be Modestly Overvalued.
Key valuation signals for NSE:BETA:
Pretax Margin %: 12.59% (10% below median its 10-year median of 13.94)
GF Value™: ₹1,965.84 vs. price of ₹2,184.70 (11.1% above fair value)
Industry Position: 72.5% above the Drug Manufacturers median (#353 of 953)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
86GF Score
Get the complete analysis for NSE:BETA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
